IRCT20140818018842N16 IRCT 2019-12-22 Hematology, Oncology & Stem Cell Transplantation Research Center, Tehran University of Medical Sci. Effect of arsenic trioxide in induction of complete remission of acute myeloid leukemia(non m3) Evaluation of the effect of arsenic trioxide adding to standard regimen 7-3 in acute myeloid leukemia patients: a Randomized single blind clinical trial 2017-12-22 anticipated 112 Complete https://irct.ir/trial/32021 interventional Randomization: Randomized, Blinding: Single blinded, Placebo: Not used, Assignment: Parallel, Purpose: Treatment, Randomization description: Patients are divided into 2 study groups by balanced block randomization. The list of randomized patients is made by a person not involved in the study and then the participants are randomly assigned into treatment groups, Blinding description: The computer gives each patient a code number. And the code numbers are then allocated to the treatment groups control(standard chemotherapy receiver) and intervention group(arsenic plus standard chemotherapy receiver). In this study, neither the participants nor the researchers know which participants belong to the placebo group, nor the intervention group. Only at the end of the study, the results are reported by a person not involved in the study. 3 Acute myeloid leukemia ( non m3). Intervention 1: intervention group: received Standard chemotherapy regimen consists of 3 days of an anthracycline e.g daunorubicin at 60 mg/m2 and 7 days of cytarabine (100 mg/m2 continuous infusion) plus arsenic at 0.15 mg/kg for 21 days. Intervention 2: control group: received standard chemotherapy regimen consist of 7 days cytarabin at 100mg/m2 and 3 days daunorubicin at 60 mg/m2. No - There is not a plan to make this available Justification or reason for not sharing IPD is There is no further information